Biomedica Joins AstraZeneca’s i2.JP to Expand Global Smart Health Solutions

We are proud to announce that Biomedica has been officially selected to join the i2.JP Innovation Platform, an AstraZeneca-led digital health accelerator based in Japan and focused on advancing healthcare innovation across the Asia-Pacific region. Biomedica is now featured on the official i2.JP partner list, alongside world-leading companies such as Fujitsu, Konica Minolta, FUJIFILM, and Nikon.

 

Launched by AstraZeneca Japan, i2.JP is a cross-sectoral platform that connects startups, medical institutions, academic researchers, and government agencies to promote the real-world implementation of cutting-edge health technologies. The platform prioritizes solutions that support digital health, AI in diagnostics, and value-based healthcare delivery.

As a new member of i2.JP, Biomedica’s selection reflects both the clinical value and international competitiveness of our AI-powered health solutions. Through this partnership, we aim to deepen collaboration with the Japanese and broader Asia-Pacific healthcare ecosystem, accelerating adoption of our osteoporosis and sarcopenia screening solutions, and expanding real-world applications in community care, hospitals, and long-term care facilities.

“We’re honored to be recognized among global healthcare leaders. This milestone not only validates our innovation but also helps bring Taiwanese smart healthcare solutions to the international stage.”
— Biomedica Team

With the support of AstraZeneca’s extensive healthcare network, Biomedica will continue to drive forward its vision of using simple, precise AI diagnostics to improve health outcomes and promote accessible, preventive care globally.